223 related articles for article (PubMed ID: 21400111)
1. Cryoimmunology for malignant bone and soft-tissue tumors.
Nishida H; Yamamoto N; Tanzawa Y; Tsuchiya H
Int J Clin Oncol; 2011 Apr; 16(2):109-17. PubMed ID: 21400111
[TBL] [Abstract][Full Text] [Related]
2. TNF-α and tumor lysate promote the maturation of dendritic cells for immunotherapy for advanced malignant bone and soft tissue tumors.
Miwa S; Nishida H; Tanzawa Y; Takata M; Takeuchi A; Yamamoto N; Shirai T; Hayashi K; Kimura H; Igarashi K; Mizukoshi E; Nakamoto Y; Kaneko S; Tsuchiya H
PLoS One; 2012; 7(12):e52926. PubMed ID: 23300824
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
Kawano M; Itonaga I; Iwasaki T; Tsumura H
Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
[TBL] [Abstract][Full Text] [Related]
4. Anti-TGF-β antibody combined with dendritic cells produce antitumor effects in osteosarcoma.
Kawano M; Itonaga I; Iwasaki T; Tsuchiya H; Tsumura H
Clin Orthop Relat Res; 2012 Aug; 470(8):2288-94. PubMed ID: 22415727
[TBL] [Abstract][Full Text] [Related]
5. Re-implantation of tumour tissue treated by cryotreatment with liquid nitrogen induces anti-tumour activity against murine osteosarcoma.
Nishida H; Tsuchiya H; Tomita K
J Bone Joint Surg Br; 2008 Sep; 90(9):1249-55. PubMed ID: 18757969
[TBL] [Abstract][Full Text] [Related]
6. [Bone and soft-tissue tumors].
Shirai Y; Nakase T
Gan To Kagaku Ryoho; 1986 Jan; 13(1):30-6. PubMed ID: 3002285
[TBL] [Abstract][Full Text] [Related]
7. Current status of immunotherapy for sarcomas.
Miwa S; Nishida H; Tsuchiya H
Immunotherapy; 2017 Dec; 9(16):1331-1338. PubMed ID: 29185391
[TBL] [Abstract][Full Text] [Related]
8. A Review of T-Cell Related Therapy for Osteosarcoma.
Yoshida K; Okamoto M; Aoki K; Takahashi J; Saito N
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664248
[TBL] [Abstract][Full Text] [Related]
9. Phase 1/2 study of immunotherapy with dendritic cells pulsed with autologous tumor lysate in patients with refractory bone and soft tissue sarcoma.
Miwa S; Nishida H; Tanzawa Y; Takeuchi A; Hayashi K; Yamamoto N; Mizukoshi E; Nakamoto Y; Kaneko S; Tsuchiya H
Cancer; 2017 May; 123(9):1576-1584. PubMed ID: 28241093
[TBL] [Abstract][Full Text] [Related]
10. Characterization of CD34+ progenitor-derived dendritic cells pulsed with tumor cell lysate for a vaccination strategy in children with malignant solid tumors and a poor prognosis.
Ackermann B; Tröger A; Glouchkova L; Körholz D; Göbel U; Dilloo D
Klin Padiatr; 2004; 216(3):176-82. PubMed ID: 15175963
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for osteosarcoma: Where do we go from here?
Wedekind MF; Wagner LM; Cripe TP
Pediatr Blood Cancer; 2018 Sep; 65(9):e27227. PubMed ID: 29923370
[TBL] [Abstract][Full Text] [Related]
12. A new antisarcoma strategy: multisubtype heat shock protein/peptide immunotherapy combined with PD-L1 immunological checkpoint inhibitors.
Li H; Sui X; Wang Z; Fu H; Wang Z; Yuan M; Liu S; Wang G; Guo Q
Clin Transl Oncol; 2021 Aug; 23(8):1688-1704. PubMed ID: 33792840
[TBL] [Abstract][Full Text] [Related]
13. The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma.
Wang SD; Li HY; Li BH; Xie T; Zhu T; Sun LL; Ren HY; Ye ZM
Int Immunopharmacol; 2016 Sep; 38():81-9. PubMed ID: 27258185
[TBL] [Abstract][Full Text] [Related]
14. Cryoimmunologic antitumor effects enhanced by dendritic cells in osteosarcoma.
Kawano M; Nishida H; Nakamoto Y; Tsumura H; Tsuchiya H
Clin Orthop Relat Res; 2010 May; 468(5):1373-83. PubMed ID: 20232181
[TBL] [Abstract][Full Text] [Related]
15. Clinical and immunological characteristics of sarcomas patients with clonogenic tumors.
Avdonkina NA; Danilova AB; Nekhaeva TL; Prosekina EA; Emelyanova NV; Novik AV; Girdyuk DV; Gafton GI; Baldueva IA
Immunobiology; 2021 Jul; 226(4):152094. PubMed ID: 34052775
[TBL] [Abstract][Full Text] [Related]
16. Progress and opportunities for immune therapeutics in osteosarcoma.
Lettieri CK; Appel N; Labban N; Lussier DM; Blattman JN; Hingorani P
Immunotherapy; 2016 Oct; 8(10):1233-44. PubMed ID: 27605071
[TBL] [Abstract][Full Text] [Related]
17. Emerging Targeted and Immune-Based Therapies in Sarcoma.
Pollack SM; Ingham M; Spraker MB; Schwartz GK
J Clin Oncol; 2018 Jan; 36(2):125-135. PubMed ID: 29220291
[TBL] [Abstract][Full Text] [Related]
18. Local Control of Soft Tissue and Bone Sarcomas.
Crompton JG; Ogura K; Bernthal NM; Kawai A; Eilber FC
J Clin Oncol; 2018 Jan; 36(2):111-117. PubMed ID: 29220297
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Targets for Bone and Soft-Tissue Sarcomas.
Miwa S; Yamamoto N; Hayashi K; Takeuchi A; Igarashi K; Tsuchiya H
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621224
[TBL] [Abstract][Full Text] [Related]
20. Specific antitumor effects of tumor vaccine produced by autologous dendritic cells transfected with allogeneic osteosarcoma total RNA through electroporation in rats.
Yu Z; Sun H; Zhang T; Yang T; Long H; Ma B
Cancer Biol Ther; 2009 May; 8(10):973-80. PubMed ID: 19287216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
